000 | 01432 a2200397 4500 | ||
---|---|---|---|
005 | 20250514004420.0 | ||
264 | 0 | _c20010920 | |
008 | 200109s 0 0 ita d | ||
022 | _a0034-1193 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aModlin, I M | |
245 | 0 | 0 |
_a[Efficacy and safety of intravenously administered pantoprazole in the treatment of gastrinoma]. _h[electronic resource] |
260 |
_bRecenti progressi in medicina _c |
||
300 |
_a456-61 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Comparative Study; Journal Article; Multicenter Study | ||
650 | 0 | 4 | _a2-Pyridinylmethylsulfinylbenzimidazoles |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 | _aAged |
650 | 0 | 4 |
_aAnti-Ulcer Agents _xadministration & dosage |
650 | 0 | 4 |
_aBenzimidazoles _xadministration & dosage |
650 | 0 | 4 |
_aEnzyme Inhibitors _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aGastric Acid _xmetabolism |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInfusions, Intravenous |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aMultiple Endocrine Neoplasia Type 1 _xdrug therapy |
650 | 0 | 4 |
_aOmeprazole _xanalogs & derivatives |
650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
650 | 0 | 4 | _aPantoprazole |
650 | 0 | 4 |
_aSulfoxides _xadministration & dosage |
650 | 0 | 4 | _aTime Factors |
650 | 0 | 4 |
_aZollinger-Ellison Syndrome _xdrug therapy |
773 | 0 |
_tRecenti progressi in medicina _gvol. 92 _gno. 7-8 _gp. 456-61 |
|
999 |
_c11403115 _d11403115 |